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SIGNIFICANCE
Pain and discomfort are relevant issues affecting patients 
with various dermatoses. This study included a large group 
of outpatients from 13 European countries, and revealed 
that pain and discomfort frequently affect dermatological 
patients, especially those with hidradenitis suppurativa, leg 
ulcer, prurigo and lichen planus.
Pain and discomfort are important symptoms in derma-
tology. The aim of this cross-sectional, multicentre stu-
dy was to describe the prevalence of pain/discomfort 
and its associations in patients with several dermato-
logical conditions across 13 European countries. The 
outcome was the prevalence of pain/discomfort ac-
cording to a question of the EQ-5D questionnaire. Data 
collected from November 2011 to February 2013 were 
complete for 3,509 consecutive outpatients. Moderate 
or extreme pain/discomfort was reported by 55.5% of 
patients and 31.5% of controls with no skin conditions. 
The highest proportions were reported by patients with 
hidradenitis suppurativa (92.9%), leg ulcer (81.4%), 
prurigo (80%) and lichen planus (75.6%). Pain/dis-
comfort was associated with older age, low educatio-
nal level, clinical severity, flare on scalp or hands, itch, 
depression, anxiety, low quality of life, and thoughts 
of suicide. It is important to enquire specifically about 
pain/discomfort during clinical consultations and to 
address it when planning a patient’s care. 
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Pain and discomfort may be experienced by patients with dermatological conditions (1, 2). Pain has been 
defined as “an unpleasant sensory and emotional expe-
rience associated with actual or potential tissue damage, 
or described in terms of such damage” (3). This definition 
is still current, as it clearly defines pain as a subjective 
experience. Moreover, it links pain to both the sensory 
systems’ physiology and to the neurobiology of emotions, 
and it specifies that pain is associated with a specific ade-
quate stimulus (4). Pain is an important symptom to be 
aware of clinically, since it is associated with profound 
effects on many aspects of quality of life (QoL) in many 
diseases (5).
The concept of discomfort is less well defined than pain, 
and has a slightly different meaning in different languages. 
In English “discomfort” may be defined as “slight pain” 
(Oxford English Dictionary), as “a painful feeling in part 
of your body when you have been hurt slightly or when 
you have been uncomfortable for a long time” (Collins 
English Dictionary), but also as the “feeling of being un-
comfortable physically or mentally” (Cambridge English 
Dictionary). In a study that aimed to create a questionnaire 
on discomfort of body skin (6), 7 items were identified from 
consumers and confirmed by dermatologists’ experience: 
stinging, itching, tightness and warming, reported by the 
patient, and dryness, redness and desquamation, evaluated 
by the dermatologist.
Skin conditions are frequently responsible for unplea-
sant sensory symptoms, most obviously itch. However, 
pain, burning, and fatigue are also present in a large 
proportion of patients with skin conditions (2, 7, 8). In 
particular, pain is often reported by patients with psoriasis, 
atopic dermatitis (AD), and leg ulcers (8–11). However, 
only a few studies have investigated pain in other skin 
conditions (2, 7, 12, 13). Also, the presence of other un-
pleasant sensations that contribute to discomfort, such as 
stinging, tightness and warming, has been rarely investi-
gated. This emphasizes the need to explore in more detail 
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the presence of unpleasant sensory symptoms in patients 
with a wide variety of skin conditions. To do this, we used 
the question from the EuroQoL-5D (EQ-5D) instrument 
that asks about the presence of pain/discomfort. The study 
was conducted in a large sample of patients with several 
dermatological conditions across 13 European countries. 
MATERIALS AND METHODS
Study population
This report presents data from a large, multicentre, epidemiological 
study on the psychological burden of skin conditions. Methods 
have been described previously in detail (14). In brief, consecutive 
patients were recruited from dermatological outpatient clinics in 13 
European countries from November 2011 to February 2013. Each 
centre had to collect data on 250 patients and 125 controls. Patients’ 
inclusion criteria were: age 18 years and over; being able to read and 
write the local language; having provided written informed consent. 
Patients were excluded if they had severe psychiatric conditions. The 
control group was recruited among employees at each study centre. 
The inclusion criteria were: age 18 years or more and no presence 
of skin condition, having provided written informed consent.
Collected data
Each patient was clinically examined by a dermatologist, who 
also collected information on comorbidities. The clinical severity 
of the skin condition was evaluated by the physician as either 
“mild”, “moderate” or “severe”. Patients were asked to com-
plete a questionnaire with socio-demographic data and several 
questionnaires on the psychological burden of skin conditions. 
The clinical evaluation and the patient’s self-assessment were 
independent of each other. 
Evaluation of pain or discomfort: the EQ-5D
The EQ-5D (15) questionnaire allows measurement of health-related 
QoL across all medical fields and across the general population. It 
has been used in skin conditions (16, 17), showing a good overall 
validity, especially for psoriasis and psoriatic arthritis (16). The EQ-
5D includes a visual analogue scale (VAS) for self-rated health state 
from “0” (worst imaginable health state) to “100” (best imaginable 
health state), and 5 questions on mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression. Each question has 3 poss-
ible answers. In this study we used data based on the question that 
asked subjects to rate “pain/discomfort” as either “I have no pain 
or discomfort” (score=0), or “I have moderate pain or discomfort” 
(score=1), or “I have extreme pain or discomfort” (score=2). 
Depression and anxiety: the Hospital Anxiety and Depression Scale 
questionnaire
Symptoms of depression and/or anxiety in patients were evaluated 
using the Hospital Anxiety and Depression Scale (HADS) (18). It 
consists of 7 items assessing anxiety (HADS-A) and 7 assessing 
depression (HADS-D), each with 4 possible answers. For each 
dimension of anxiety and depression a person with a score of 0–7 
is considered a normal case, 8–10 a borderline case, and 11–21 a 
case in need of further examination or treatment. In this paper we 
describe a subject with a score of 11–21 as a “clinical case”, and 
with a score of 8–10 as a “borderline case”. Although the EQ-5D 
asks about depression and/or anxiety, this is only an exploratory 
question that does not distinguish between the 2 conditions; hence 
the need to also use HADS as a screening tool to identify depres-
sion or anxiety separately.
Quality of life: the Dermatology Life Quality Index
Dermatology-specific health-related QoL was assessed using the 
Dermatology Life Quality Index (DLQI) (19). It consists of 10 
questions, with possible answers from 0 (“not at all”) to 3 (“very 
much”). The total score is obtained by adding the score of each 
item. The following score band descriptors have been validated 
(20): total score 0–1: no effect at all on patient’s life; 2–5: small 
effect on patient’s life; 6–10: moderate effect on patient’s life; 
11–20: very large effect on patient’s life; and 21–30: extremely 
large effect on patient’s life.
Suicidal ideation
To assess suicidal ideation due to the skin condition, the item 
‘’Have you ever thought of committing suicide because of your 
skin?’’ was included, with possible answers ‘’yes’’ or ‘’no’’. 
Sample size
As previously described (14), the statistical power was calcula-
ted on the basis of the prevalence of depression in the general 
population, estimated as 9%, and the expected prevalence in the 
dermatological population being higher (21). To identify a diffe-
rence with a power of 0.80 and alpha=0.05 between a prevalence 
of depression of 9% in controls and 11% in cases, using a 1-sided 
test, 3,500 cases and 1,300 controls were needed (233 cases and 
87 controls in each centre).
Statistical analysis
The answers to the “pain/discomfort” question of the EQ-5D were 
dichotomized into a variable “yes/no” by grouping the answers “I 
have moderate pain or discomfort” and “I have extreme pain or 
discomfort”. The frequency of pain/discomfort for the different der-
matological conditions was calculated, and graphically represented 
by histograms. The group “psychodermatological diseases” inclu-
ded patients with factitial dermatitis, burning mouth, psychogenic 
itch, and trichotillomania. The association of pain with different 
variables was calculated: socio-demographic variables (sex, age, 
“living in the country of origin”, education, marital status, geo-
graphical region); clinical information (clinical severity of the skin 
condition, body site of the disease, presence of itch); presence of 
depression, presence of anxiety, suicidal thoughts, and DLQI score. 
The associations were analysed using odds ratios (ORs). Countries 
were grouped into Northern Europe (Denmark, Norway), Western 
Europe (Belgium, France, Germany, The Netherlands, UK), Eastern 
Europe (Hungary, Poland, Russia, Turkey), and Southern Europe 
(Italy, Spain). Logistic regression models were tested to estimate 
the degree of association of each variable of interest with pain/
discomfort, while adjusting for all the other variables in the model. 
The dichotomous variable “pain/discomfort yes/no” was introduced 
in each model as the dependent variable. The independent variables 
were: sex, age, marital status, clinical severity, itch, depression, 
anxiety, and DLQI. Separate models were created for some diseases, 
selected on the basis of the number of patients (approximately 200 
patients or more), i.e. psoriasis, eczema, non-melanoma skin cancer 
(NMSC), and acne. The diagnosis “eczema” included AD, eczema 
and hand eczema. 
RESULTS
In total, 5,067 individuals agreed to participate; 3,651 
patients and 1,416 controls. The participation rate was 
79.9%. Of the initial 3,651 patients, 16 were excluded, 9 
because they were too young and 6 because of missing 
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subsequently excluded because, in the questionnaire spe-
cific for controls, they reported being treated for a skin 
disease, leaving 1,359. Information on pain/discomfort 
was available in 3,509 patients (96.5%). In the study 
population 43.6% were males, and the mean ± standard 
deviation age was 46.9 ± 17.2 years. 
The disease was evaluated by the clinician as severe in 
16.6% of patients, moderate in 45.3%, and mild in 38.1%. 
Clinical or borderline depression were present in 10.1% 
and 14.0% of patients, respectively (total prevalence of 
depression in cases 24.1%); clinical or borderline anx-
iety in 17.2% and 19.9%, respectively (total prevalence 
of anxiety in cases 37.1%). In patients, the presence of 
some pain/discomfort was reported by 49.7% of patients 
and extreme pain/discomfort by 5.8% (total prevalence 
55.5%). In controls, these figures were 30.1% and 1.4%, 
respectively (total prevalence 31.5%). The prevalence ob-
served in controls was quite high; however, it is consistent 
with that reported in other studies (22). Furthermore, while 
the overall prevalence rate ratio (PRR) of moderate or 
extreme pain/discomfort was 1.8, when considering only 
extreme pain, the PRR was 4.1. In the 4 geographical areas 
PRR of moderate or extreme pain/discomfort was quite 
homogeneous, varying from 1.5 in Western Europe to 2.0 
in Southern Europe. The highest proportion of presence 
of pain/discomfort (Fig. 1) was reported by patients with 
hidradenitis suppurativa (92.9%), leg ulcer (81.4%), pru-
rigo (80%), lichen planus (75.6%), and pruritus (75.0%). 
Patients reporting pain/discomfort were less frequently 
those with vitiligo (21.7%), naevi (23.6%), and acne 
(24.5%). The conditions with a higher prevalence of fre-
quent pain/discomfort were prurigo (28.0%) and hyperhi-
drosis (27.3%). Pain/discomfort was associated with older 
age, low educational level, high clinical severity, flare on 
scalp or hands, and itch (Table I). It was less frequently 
reported by single patients or by patients with a flare on 
the face. As to mood disorders (Table II), the presence 
of borderline/clinical depression and anxiety, as well as 
Fig. 1. Prevalence of positive 
answers (“moderate” or 
“extreme”) to the question 
on the presence of pain/
discomfort of the EuroQoL-
5D (EQ-5D) questionnaire 
in different skin conditions. 
Data from 3,509 outpatients 
collected from November 2011 
to February 2013. Red line 
indicates the prevalence of 
positive answers in controls.
thoughts of suicide, were strongly associated with pain/
discomfort. The association between pain/discomfort and 
QoL increased substantially with increasing impairment in 
QoL, ranging from an OR of 2.18 for a small impairment 
of QoL up to 23.48 for a major impairment.
The multivariate models for single diseases (Table III) 
confirmed the strong association between pain/discomfort 
and low QoL in psoriasis, eczema, acne, and NMSC. 
Pain/discomfort was also significantly associated with 
the presence of anxiety in psoriasis, eczema, and acne. In 
psoriasis and acne, pain/discomfort was associated with 
itch. Age was positively associated with pain/discomfort 
in psoriasis and eczema.
DISCUSSION
In this study of a large number of dermatology outpatients, 
moderate or extreme pain/discomfort was reported by 
55.5% of patients. The proportion was particularly high in 
patients with hidradenitis suppurativa, leg ulcer, prurigo, 
and lichen planus. Between 65% and 75% of patients with 
pruritus, blistering disorders, connective tissue disease, 
psychodermatological conditions, eczema, and pruritus ex-
perienced some or extreme pain/discomfort. These results 
are not directly comparable with those of previous studies, 
where only the dimension of pain was considered, or pain 
and discomfort were measured separately. For example, 
in a study of over 1,500 dermatological outpatients who 
used a specific questionnaire for neuropathic pain (7), 
skin pain was reported by 36.4% of patients. In another 
study (2), 23% of patients with skin diseases experienced 
pain evaluated with a VAS. Ljosaa et al. (9) reported a 
prevalence of 42% of skin pain and 37% of discomfort in 
patients with psoriasis. On the basis of these results we can 
speculate that approximately half of our patients reporting 
pain/discomfort actually had pain, and half had discomfort. 
This would be consistent with the results of the previous 
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In the current study, pain/discomfort was strongly asso-
ciated with poor QoL, as also previously observed (1). We 
reported a significant association between pain/discomfort 
and both depression and anxiety. The association with 
anxiety was particularly strong, since it was significant 
even in the multivariate models when considering single 
conditions, such as psoriasis, eczema, and acne. It has 
been observed, in the musculoskeletal domain, that anx-
iety disorders, as well as other psychological symptoms, 
are associated with high levels of perceived pain (23, 24). 
According to the biopsychosocial model (25), there might 
be a bidirectional relationship between anxiety/depres-
sion and pain, including skin pain (26). Concerning the 
association with suicidal thoughts in the current study, 
the number of subjects was not large enough to know if 
suicidal thoughts were due to pain, especially as suicidal 
ideation was reported by a relatively small proportion of 
the participants. However, we have run a crude analysis 
for the association between pain and suicidal ideation, 
stratified by diagnosis. In general, we have observed 
that suicidal ideation was more frequent among patients 
reporting higher levels of pain/discomfort.
In the current study, pain/discomfort was more frequent 
in older patients. This could be due also to the presence 
of comorbidities. In fact, the EQ-5D question does not 
specify if pain/discomfort is due to a skin condition. This 
lack of specificity and presence of co-morbidities may also 
explain the reporting of pain/discomfort in conditions such 
as naevi and vitiligo.
Almost all patients with hidradenitis suppurativa repor-
ted moderate or extreme pain/discomfort. It is known that, 
among inflammatory dermatoses, hidradenitis suppurativa 
has the highest impact on QoL (27), presumably because 
of the frequent presence of symptoms, such as pain. Our 
results emphasize the importance of taking into account 
pain management when planning a treatment strategy for 
this condition (28). 
Various studies with different samples and assessment 
methods have reported a range of percentages of patients 
with psoriasis experiencing pain. For example, in one study 
(8) 26% of psoriasis patients reported pain (up to 50% for 
psoriatic arthritis), but in that study a stringent definition of 
pain as experienced “often” or “all the time” was adopted. 
In the study by Ljosaa et al. (9), skin pain was reported 
by 42% of psoriasis patients, while in our study moderate 
or extreme pain/discomfort was reported by 66.3% of 
patients. In patients with psoriasis, pain was also strongly 
associated with the presence of itch. This is not surprising, 
since mechanisms that underlie the development of chronic 
itch and pain may overlap to a great extent (29). 
Pain is present in patients with AD (30). Patients may 
scratch their skin, resulting in skin barrier disruption and 
painful erosions, but pain could also be partly related to 
neurogenic inflammation (31). In a previous study (11), 
pain and itch occurred together in 78% of patients with AD. 
It was observed that the presence of pain had an important 
impact on QoL, since it interfered with sleep, leisure 
activities, and daily living. In our study population, pain 
was strongly associated with older age and with anxiety. 
Table II. Prevalence of patients experiencing pain/discomfort in 
the study population according to psychological conditions and 
quality of life
Variable n (%)* OR (95% CI)
No depression 2,636 (49.8) 1
Borderline depression 486 (70.8) 2.44 (1.97–3.03)
Clinical depression 347 (77.8) 3.54 (2.69–4.65)
No anxiety 2,173 (47.1) 1
Borderline anxiety 698 (65.9) 2.17 (1.81–2.61)
Clinical anxiety 590 (73.9) 3.18 (2.59–3.92)
No thoughts of suicide 3,249 (54.2) 1
Thoughts of suicide 234 (73.9) 2.40 (1.76–3.28)
Dermatology Life Quality Index
  No 969 (31.4) 1
  Small 919 (49.9) 2.18 (1.80–2.64)
  Moderate 680 (65.9) 4.22 (3.41–5.23)
  Very large 701 (76.6) 7.16 (5.71–8.99)
  Extreme 176 (91.5) 23.48 (13.26–42.23)
Data from 3,509 outpatients collected in 13 European countries from November 
2011 to February 2013.
*Totals may vary because of missing values. OR: odds ratio; CI: confidence interval. 
Bold numbers indicate statistically significant association.
Table I. Prevalence of patients experiencing pain/discomfort in the 
study population according to demographic and clinical variables
Variable n (%)* OR (95% CI)
Sex
  Male 1,523 (53.9) 1
  Female 1,974 (56.6) 1.12 (0.97–1.28)
Age
  18–40 years 1,314 (46.3) 1
  41–60 years 1,177 (58.2) 1.61 (1.37–1.89)
  > 60 years   956 (65.1) 2.16 (1.30–2.58)
Origin
  Home 3,186 (55.0) 1
  Foreign   245 (59.6) 1.21 (0.92–1.59)
Education
  Primary 1,431 (57.4) 1
  Secondary 1,039 (56.9) 0.98 (0.83–1.15)
  University 1,006 (51.2) 0.78 (0.66–0.92)
Marital status
  Single   837 (45.5) 1
  Married 1,851 (55.3) 1.48 (1.25–1.74)
  Divorced 268 (65.7) 2.29 (1.70–3.08)
  Widow 198 (76.8) 3.96 (2.73–5.74)
Region
  Eastern Europe 945 (53.8) 1
  Northern Europe 736 (58.3) 1.20 (0.99–1.46)
  Western Europe 1,080 (55.0) 1.05 (0.88–1.25)
  Southern Europe   748 (55.9) 1.09 (0.90–1.32)
Severity
  Mild 1,189 (46.3) 1
  Moderate 1,415 (59.6) 2.25 (1.93–2.63)
  Severe   517 (66.9) 3.09 (2.48–3.84)
Flare on face
  Yes 1,272 (51.9) 1
  No 2,159 (57.9) 1.28 (1.11–1.47)
Flare on scalp
  Yes   910 (62.3) 1.45 (1.23–1.69)
  No 2,527 (53.3) 1
Flare on hands
  Yes 1,042 (67.1) 1.98 (1.69–2.31)
  No 2,394 (50.8) 1
Itch
  Yes 1,576 (68.3) 3.18 (2.76–3.67)
  No 1,869 (40.4) 1
Data from 3,509 outpatients collected in 13 European countries from November 
2011 to February 2013. *Totals may vary because of missing values.
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There has been little investigation of pain in acne. 
In our population 24.5% of patients reported that they 
had experienced moderate or extreme pain/discomfort, 
which was associated with itch, anxiety, and poor QoL. 
We suggest that in acne pain is directly caused by the 
inflammatory lesions and may be exacerbated by trauma 
or manual interference with the lesions.
Pain was also present in patients with NMSC. In a pre-
vious study (32), 57.5% of patients with squamous cell 
carcinoma reported spontaneous pain, and 80% reported 
pressure-related pain. Patients with basal cell carcinoma 
may also report pain, in particular as a major side-effect 
of topical photodynamic therapy (33). In our study, pain/
discomfort was reported by 44.3% of patients with NMSC. 
Pain is more frequently associated with squamous cell 
carcinoma than other skin cancers (34) and is frequently 
(but not exclusively) associated with perineural invasion.
Other studies have used the EQ-5D questionnaire in 
dermatology (17, 35), but none have previously analysed 
a single dimension. The analysis of single items of a ques-
tionnaire may give important information on the burden on 
patients of a particular symptom or psychosocial problem 
on patients (36). Our previous European group paper 
presenting EQ-5D data (17) focused on a different study 
question, i.e. the comparison between dermatological 
cases and non-dermatological controls. 
A possible issue of the use of the question about pain/
discomfort concerns the translation of the term “dis-
comfort” into different languages. 
The word “discomfort” does not 
have such a well-defined meaning 
as “pain”. The number of words 
that express a sensation, such as 
tingling, prickling and stinging, 
differs depending on the language 
used (37). High-standard validated 
translations and cross-cultural adap-
tations are crucial to ensure equi-
valence of meaning, as previously 
shown in a comparative study on 
pain (38). However, the original 
selection of the dimensions of the 
EQ-5D questionnaire was done on 
the basis of a survey of patients and 
the general population, and of a de-
tailed review of other generic health 
measures (39). The dimension of 
pain/discomfort was chosen taking 
into account the translation issues. 
Moreover, the combination of the 
2 terms has been used previously; 
for example, in a study on patients 
with psoriasis (40).
A strength of this study is that 
it includes data from a multicen-
tre European initiative aimed at 
providing insight to the impact of 
skin diseases on QoL and psychological well-being. This 
involved the collection of a large amount of data using 
a single study design with standardized procedures and 
common research tools. There were no differences among 
regions in the prevalence of pain, which may indicate that 
it is the skin condition, and not factors specific to each 
country (health policy, climate, etc.), that influences the 
degree of pain/discomfort. 
A limitation of the current study is the cross-sectional 
design, which does not allow determination of the direc-
tion of the associations between pain/discomfort and 
the other variables. Thus, for example, it is not possible 
to know if people with depression thereby experienced 
more pain/discomfort, or if the presence of more pain/
discomfort may cause depression in some people. Another 
limitation of the study is that the EQ-5D question does 
not distinguish pain and discomfort. This may hinder 
comparisons with the results of other studies where pain 
or other unpleasant sensations are investigated separately. 
In conclusion, pain/discomfort is a common symptom 
in several skin conditions, and is associated with a poor 
QoL, mood disorders and anxiety. Dermatologists should 
be aware of this, should enquire specifically about these 
very common symptoms in their routine clinical practice, 
and, when necessary, refer patients to a pain management 
specialist. In particular, the EQ-5D is a simple instrument 
that can be used in clinical practice to obtain information 
on specific aspects, such as pain/discomfort. 
Table III. Logistic regression models for psoriasis, eczema, acne, and non-melanoma skin 
cancer (NMSC) patients, with pain/discomfort from the EuroQoL-5D (EQ-5D) questionnaire 
as the dependent variable
Psoriasis (n = 491) 
OR (95% CI)
Eczema (n = 410)
OR (95% CI)
Acne (n = 197)
OR (95% CI)
NMSC (n = 271)
OR (95% CI)
Sex
  Male Ref. Ref. Ref. Ref.
  Female 1.05 (0.67–1.65) 1.39 (0.88–2.20) 0.83 (0.38–1.78) 0.85 (0.50–1.44)
Age, 
  18–39 years Ref. Ref. Ref. Ref.
  40–59 years 1.05 (0.63–1.73) 2.18 (1.24–3.84) 3.13 (0.35–28.28) 0.74 (0.20–2.70)
  > 60 years 3.08 (1.57–6.04) 3.27 (1.52–7.04) –– 1.57 (0.45–5.44)
Marital status
  Single Ref. Ref. Ref. Ref.
  Married 1.50 (0.88–2.56) 1.11 (0.64–1.92) 1.78 (0.73–4.32) 1.02 (0.33–3.13)
  Divorced (widow(er) 2.52 (1.10–5.79) 0.64 (0.28–1.44) 4.82 (0.15–154.49) 1.39 (0.40–4.86)
Severity
  Mild Ref. Ref. Ref. Ref.
  Moderate 1.39 (0.84–2.30) 1.51 (0.92–2.47) 1.13 (0.49–2.61) 1.09 (0.61–1.95)
  Severe 1.54 (0.83–2.85) 1.26 (0.60–2.66) 1.72 (0.58–5.03) 0.99 (0.47–2.10)
Itch
  No Ref. Ref. Ref. Ref.
  Yes 2.80 (1.71–4.60) 1.06 (0.59–1.92) 2.19 (1.01–4.72) 1.66 (0.96–2.86)
Depression
  No Ref. Ref. Ref. Ref.
  Yes 1.51 (0.81–2.80) 1.07 (0.57–2.00) 1.70 (0.67–4.32) 1.84 (0.76–4.43)
Anxiety
  No Ref. Ref. Ref. Ref.
  Yes 1.70 (1.02–2.83) 2.36 (1.34–4.18) 3.04 (1.39–6.69) 1.12 (0.59–2.14)
DLQI
  No Ref. Ref. Ref. Ref.
  Small/moderate 2.01 (1.11–3.66) 3.38 (1.64–6.99) 3.38 (1.01–11.28) 2.35 (1.33–4.16)
  Very large/extreme 4.29 (2.19–8.42) 6.41 (2.87–14.32) 1.66 (0.39–7.08) 4.60 (0.76–27.81)
Each variable is adjusted for all the other variables. Data from 3,509 outpatients collected in 13 European countries 
from November 2011 to February 2013.
DLQI: Dermatology Life Quality Index; EQ-5D: EuroQoL-5D questionnaire; OR: odds ratio; CI: confidence interval. 
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